NVO Novo Nordisk A/S Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
00:13
Jul 18
Jul 18
Price observation of drawdown, no directional view or catalyst from speaker.
LOW
07:45
Jul 17
Jul 17
Author discloses an active long position in NVO, currently up 40% over three months, framed as part of a diversified portfolio strategy away from crowded AI/high-beta names.
MED
14:43
Jul 16
Jul 16
Price observation on NVO relative to moving averages, no directional view or catalyst.
LOW
19:07
Jul 15
Jul 15
Author shares European approval news for Wegovy pill/Sema 7.2mg with a bullish reaction, but does not state a buy, position, or actionable forward call for NVO.
LOW
15:51
Jul 15
Jul 15
Novo Nordisk plans to introduce its Wegovy pill in more countries during the latter half of 2026.
15:51
Jul 15
Jul 15
Novo Nordisk's oral weight loss drug Wegovy receives European Commission approval along with a new higher dosage pen formulation.
14:38
Jul 15
Jul 15
Buy NVO on mean-reversion thesis; stock has been severely beaten down over the past year and author expects a rotation bid into neglected, out-of-favor names.
MED
01:31
Jul 15
Jul 15
Headline reports Novo Nordisk's obesity pill outperforming Eli Lilly's; comparative competitive development, no speaker view.
LOW
23:08
Jul 13
Jul 13
Oral GLP-1s bring new users, expanding market.
Oral GLP-1 options are expanding the US market because the majority of oral users are new to GLP-1s. This market expansion is a strong growth driver, and non-peptide-based orals being easier to scale adds another dimension to monitor, while the existing oral drug is already bringing in fresh demand.
MED
12:25
Jul 11
Jul 11
Fresh ISTH 2026 data on Denecimig (Mim8) and Concizumab (Alhemo) in hemophilia A shows strong efficacy results; speaker flags pipeline as underrated but notes 29% serious side-effect rate for Concizumab and frames hemophilia as a small part of Novo's broader story.
MED
12:08
Jul 11
Jul 11
Novo Nordisk reports positive long-term safety and efficacy results for Deneicimig in Phase 3 hemophilia A extension study at ISTH 2026.
04:36
Jul 11
Jul 11
The tweet shares an article analyzing liver safety data for Lilly's Orforglipron, concluding it appears fine for now, but offers no personal position or trade call.
LOW
21:11
Jul 10
Jul 10
Author endorses MELI as a great list pick, is uncertain on NVO but thinks it's a buy while noting LLY might be the better obvious buy, creating a mixed but overall bullish tone on the sector.
LOW
21:04
Jul 10
Jul 10
The author lists five tickers in reply to a parent asking for forgotten favorites to monitor, making this a watchlist response rather than an explicit position or trade call.
LOW
18:04
Jul 07
Jul 07
The author sarcastically notes that Terry Smith's sale of Novo Nordisk suggests a loss of bullish sentiment, but does not state their own position.
13:35
Jul 07
Jul 07
Author shared an updated catalyst roadmap for Novo Nordisk covering 2026-2028, but no personal position or forward call is stated.
LOW
10:48
Jul 07
Jul 07
Author shares a catalyst roadmap for Novo Nordisk through 2028, presenting a research summary rather than a personal position or trade call.
LOW
10:17
Jul 07
Jul 07
Author mentions a catalyst roadmap and updated thesis for NVO, but asks for additional catalysts without stating a personal directional view.
LOW
14:26
Jul 05
Jul 05
The author expresses confidence in a long-term investment but does not specify the ticker, and the parent context only criticizes NVO without an explicit endorsement.
14:13
Jul 05
Jul 05
Author lists this ticker as part of their current portfolio and asks for critique; under current-position semantics this is a long/held position, though no fresh catalyst is stated.
LOW
18:44
Jul 04
Jul 04
Author explicitly lists NVO as a current portfolio holding in a monthly holdings update.
LOW
18:40
Jul 04
Jul 04
Author holds Novo Nordisk, citing compressed valuation and an imminent guidance raise as the catalyst for a sustained move above $50; stock up ~9% in June with momentum building.
MED
08:46
Jul 02
Jul 02
Novo Nordisk is currently negotiating with its various suppliers to secure discounts in an effort to reduce the company's overall operating costs.
20:26
Jul 01
Jul 01
Seeking Alpha reports Medicare's new GLP-1 cost cap and bullish market projections but notes the Quant system rates both stocks a HOLD due to high valuation, making this a research summary rather than a trade call.
11:06
Jul 01
Jul 01
Novo Nordisk announces Medicare GLP-1 bridge program for Wegovy running through end of 2027 with $50 monthly copay for eligible beneficiaries.
10:57
Jun 28
Jun 28
NVO is a potential catch-up trade within healthcare — the stock has lagged uptrending peers and may close the performance gap.
MED
12:02
Jun 26
Jun 26
Mentions Novo (Novo Nordisk) in a reply about patience, no directional view or catalyst.
LOW
10:06
Jun 26
Jun 26
Buy more NVO; author expresses strong desire to add to existing position following Goldman Sachs raising its price target on NVO, treating the PT increase as a positive catalyst despite the maintained Neutral rating.
MED
12:55
Jun 25
Jun 25
The author playfully questions a bearish view on Novo Nordisk without stating their own position or trade.
LOW
07:34
Jun 25
Jun 25
Buy NVO ahead of Q2 August report; management likely lowballed 2026 guidance in Q4-25 to de-risk the Oral Wegovy pill launch, and strong pill volume offsetting pricing headwinds sets up a guidance raise catalyst.
MED
About NVO Analyst Coverage
Buzzberg tracks NVO (Novo Nordisk A/S) across 40 sources. 129 bullish vs 6 bearish calls from 69 analysts. Sentiment: predominantly bullish (37%). 329 total trade ideas tracked. Past 7 days: 3 bullish, 6 watch. Latest voices: BarbarianCap, tacticzh, bryzonx.